Phase 2 N=14 Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Response — 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
Breast Cancer · Head and Neck Cancer · Lymphedema
Primary: Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP) — 1.51 units on a scale — p=<0.001
Phase 3 N=382 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
Diabetes Mellitus · Macular Edema
Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 33.6; 45.7; 12.3 Percentage of patients…
Phase 1 N=17 Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
Primary: The Primary Endpoint of the Study is to Establish the Maximum Tolerated Dose of Vorinostat When Given Concurrently With Palliative Radiation. — 400 mg
N/A N=351 A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System
Diagnostic Catheterization Access Through a 5F or 6F Femoral Artery Introducer
Primary: Observation of Any Site Related Complications Recorded as Either Major or Minor Adverse Events.
Phase 3 N=135 Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008
Seasonal Influenza Vaccine
Primary: Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV). — 22; 23; 624; 199 Titer
Phase 4 N=566 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
Overactive Bladder
Primary: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours — 3.93; 4.07 episodes per 24 hours
Phase 3 N=377 A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
Diabetes Mellitus · Macular Edema
Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…
N/A N=61 The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1C — 0.3; -0.1 percentage — p=>0.05
N/A N=225 Zonisamide for Weight Reduction in Obese Adults
Obesity
Primary: Change in Body Weight — -4.0; -4.4; -7.3 kg
N/A N=16 Pediatric Nasal Mask Usability Study
Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index (AHI) Using the New Pediatric Mask (Pixi) Compared to the Child's Currently-used Mask — 2.7 AHI (events/hour)
N/A N=9 Cooling Pillow for Atopic Dermatitis
Atopic Dermatitis · Eczema
Primary: Change in Sleep Quality as Measured by a Change in Pittsburgh Sleep Quality Index (PSQI) Survey Score — -1; -2 units on a scale
Phase 2 N=59 Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Brain Tumors · Osteoporosis · Central Nervous System(CNS)Malignancies
Primary: Percent of Patients With Change in Combined Bone Mass Density T-score <= -0.5. — 3.7; 10.5 percentage of patients
N/A N=100 Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting
Stroke
Primary: The Benefit of Advanced Notification in Promoting Informed Consent — 27; 25 Participants
N/A N=9 Daily Disposable Contact Lens Tear Film Study
Myopia
Primary: Number of Participants With Corrected Visual Acuity of 0.0 or Better — 9; 9; 9; 9 participants